Intercell AG

euro adhoc: Intercell AG
Joint Ventures/Cooperation/Collaboration
Intercell enters into strategic partnership with Wyeth for the use of its IC31TM adjuvant in various selected infectious disease vaccines

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- 12.09.2006 » Worldwide agreement with Wyeth for the use of Intercell's fully synthetic novel adjuvant IC31TM in various selected infectious disease vaccine programs » Up to USD 77 million in upfront, option and milestone payments as well as royalties on product net sales » Further use of Intercell’s adjuvant IC31TM in the development of novel vaccines with high unaddressed medical need. Intercell AG (VSE, "ICLL") today announced that it has closed a worldwide non-exclusive agreement under which Wyeth has the right to use Intercell's fully synthetic novel adjuvant IC31TM in various selected infectious disease vaccine programs. Under the agreement, Intercell may be entitled to receive up to USD 77 million in upfront, option and milestone payments as well as royalties on product net sales. "After having partnered a number of our vaccine candidates derived from our extremely successful Antigen Identification Program® with leading players in the vaccine industry, we are convinced that our adjuvant IC31TM will also generate significant value in the vaccine sector", says Alexander von Gabain, Intercell's Chief Scientific Officer. "We are happy that we could add Wyeth, a company with a high commitment to developing and commercializing innovative products in the vaccine sector, to the list of our top partners." About IC31TM Vaccines, based on antigens alone, are not sufficient to provide full protection. Adjuvants are needed to educate the immune system to recognize and eliminate the pathogens efficiently. IC31TM is an adjuvant that induces T-cell and B-cell responses by using a unique synthetic formulation which combines the immunostimulating properties of an anti-microbial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two component solution can be simply mixed with antigens; no conjugation is required. Intercell currently uses IC31™ in collaborations with a number of global vaccine companies and biotech companies. These collaborations include amongst others the development of a tuberculosis vaccine in Phase I clinical trials, which has been partnered with the Danish Statens Serum Institut. end of announcement euro adhoc 12.09.2006 07:10:29 -------------------------------------------------------------------------------- ots Originaltext: Intercell AG Im Internet recherchierbar: http://www.presseportal.de Further inquiry note: Intercell AG Mag. Katharina Wieser Head of Corporate Communications Tel. +43 1 20620-303 kwieser@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Börsen: Wiener Börse AG / official market

Das könnte Sie auch interessieren: